SCHEMBL1484093

SCHEMBL1484093

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1cccc(-c2ccc(O)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
LMNA P02545 1/20 0.34
KCNA3 P22001 1/20 0.34
DPP4 P27487 4/20 0.33
DPP8 Q6V1X1 3/20 0.33
DPP9 Q86TI2 3/20 0.33
GFER P55789 1/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
MARS1 P56192 1/20 0.33
RELA Q04206 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1484091 1.00 MEN1 (0.41) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1481423 0.93 LMNA (0.35) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1481420 0.93 LMNA (0.35) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1480642 0.91 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1480644 0.91 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1482165 0.88 MAPT (0.42) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1482170 0.88 MAPT (0.42) MEN1KMT2AMAPTSMN1; SMN2PTGS1
SCHEMBL1481911 0.87 ACHE (0.39) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL1481908 0.87 ACHE (0.39) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL1481692 0.85 MAPT (0.41) MEN1KMT2AMAPTSMN1; SMN2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MEN1 3467/4885KMT2A 1996/4885MAPT 3558/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MEN1 3467/4885KMT2A 1996/4885MAPT 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.